HSCLBSEHIMADRI SPECIALITY CHEM LHighNeutral
Announced Wed, 15 Jul · 15:35 IST

Q1FY27 results: revenue up 28%, PAT up 27%; board approves Rs 368 Cr capex

Revenue Growth 20pctPat Growth 25pctResults View source PDF

HSCL · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+8.8%1-day move
₹681.40
prior close
₹690.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+0.4+1.7+3.0+1.9+8.8+13.1+17.3+12.4+13.9+16.1
Up moveDown movePending
AI summary

Himadri Speciality Chemical reported Q1FY27 consolidated revenue from operations at Rs 1,431.88 Cr (up 28% YoY from Rs 1,118.29 Cr) and PAT at Rs 228.43 Cr (up 27% YoY from Rs 179.36 Cr). Board approved three capex plans totaling Rs 368 Cr funded via internal accruals: Rs 128 Cr to expand Anthraquinone and Carbazole capacity to 5300 MTPA, Rs 70 Cr for India's first Carbon Nano Tubes facility in West Bengal, and Rs 170 Cr for Super Speciality Carbon Black. Auditors Singhi & Co issued an unqualified limited review report.

Likely market impact

Strong Q1 results confirm growth momentum. Major capex in high-value specialty products signals future revenue diversification and capacity expansion.